The A2780 human ovarian cancer cell line (RRID:CVCL_0134) and their cisplatin (CDDP)-resistant counterpart, named A2780 CIS (RRID:CVCL_1942) were acquired by Sigma-Aldrich (St Louis, Missouri, USA) (Catalog Number 93,112,519 and 93,112,517, respectively). From the SKOV3 human ovarian cancer cell lines (RRID: CVCL_0532), the SKOV3 CIS-1 and SKOV3 CIS-2 (CDDP-resistant clones) were obtained as previously described [23 (link)]. These cells were grown at 37 °C in an incubator with 5% CO2 in RPMI-1640 medium (Sigma-Aldrich, St Louis, Missouri, USA), supplemented with 10% FBS, 2 mM glutamine, 100 U/mL penicillin, and 10 mg/mL streptomycin (Gibco, ThermoFisher Scientific, Waltham, MA, USA). Cells were regularly evaluated for Mycoplasma contamination.
Where indicated, cells were treated with MG132 (20 µM, Sigma-Aldrich), with cycloheximide (CHX) (50 µM, Sigma-Aldrich), carbonyl cyanide m-chlorophenylhydrazone (CCCP) (10 µM, Enzo Life Science, NY, USA), GW4869 (20 µM, Cayman Chemical Company, Ann Arbor, Michigan, USA) and with Bafilomycin A1 (400 nM, Santa Cruz Biotechnologies, Santa Cruz, CA, USA).
Where indicated, cells were treated with MG132 (20 µM, Sigma-Aldrich), with cycloheximide (CHX) (50 µM, Sigma-Aldrich), carbonyl cyanide m-chlorophenylhydrazone (CCCP) (10 µM, Enzo Life Science, NY, USA), GW4869 (20 µM, Cayman Chemical Company, Ann Arbor, Michigan, USA) and with Bafilomycin A1 (400 nM, Santa Cruz Biotechnologies, Santa Cruz, CA, USA).